APRE — Aprea Therapeutics Share News
0.000.00%
Last trade - 00:00- $6.52m
- -$33.99m
- $0.29m
Brief: Aprea Therapeutics Announces Pricing Of $5.5 Million Underwritten Public Offering Of Common Stock
Brief: Aprea Therapeutics Announces One-For-Twenty Reverse Stock Split
Brief: Aprea Therapeutics Appoints John Hamill As CFO
U.S. STOCKS ON THE MOVE-Tesla, Eton Pharma, Jack Henry & Associates
U.S. STOCKS ON THE MOVE-Levi Strauss, Salesforce, Eli Lilly
Brief: Aprea Therapeutics Announces Dosing Of First Patient In Phase 1/2a Clinical Trial Of ATRN-119
Aprea Therapeutics gains as dosing begins in cancer drug trial
Brief: Aprea Therapeutics Says Staff Of Nasdaq Determined That Co Has Regained Compliance With Minimum $10 Mln Stockholders' Equity Requirement Rule
Aprea Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Aprea Therapeutics Reports Third Quarter 2022 Financial Results
Aprea Therapeutics Inc expected to post a loss of 28 cents a share - Earnings Preview
Brief: Aprea Therapeutics Got Notice From Nasdaq Notifying That Co Did Not Satisfy Certain Continued Listing Requirement
Aprea Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Aprea Therapeutics Reports Q2 Net Loss $98.3 Mln Or $4.34 Per Share
Aprea Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview
Aprea Therapeutics hits near 2-month high after Wedbush's 'outperform' rating
U.S. RESEARCH ROUNDUP- BlackRock, Blueprint Medicines, MRC Global
Brief: Aprea Therapeutics- On June 29 Co Got Deficiency Letter From Nasdaq Regarding Minimum Bid Price Requirement
Aprea Therapeutics Inc reports results for the quarter ended in March - Earnings Summary